The JAG2 Knockout TE1 Polyclonal Cells consist of a CRISPR/Cas9-edited polyclonal knockout cell population generated from the human TE1 esophageal squamous cell carcinoma cell line. This product serves as a loss-of-function tool for investigating JAG2, a gene encoding a Notch ligand that governs cell fate determination, proliferation, and differentiation. As a polyclonal pool, the cells encompass a heterogeneous set of targeted disruptions, minimizing clonal artifacts and enhancing reproducibility in functional studies. Researchers can confidently employ this model to explore JAG2-mediated signaling in a disease-relevant epithelial tumor background.
The TE1 host cell line is a well-differentiated human esophageal squamous cell carcinoma line that maintains key epithelial traits and is widely adopted in cancer research. Its genetic and phenotypic stability makes it suitable for interrogating tumor-specific signaling mechanisms. By introducing a JAG2 knockout in TE1 cells, this product offers a direct means to assess the contribution of this Notch ligand to esophageal carcinoma cell behavior, including growth, motility, and response to external stimuli.
At the molecular level, JAG2 is a transmembrane ligand that engages Notch receptors (NOTCH1, NOTCH2, NOTCH3, NOTCH4). Ligand binding triggers sequential proteolysis by ADAM10 and the ??-secretase complex, releasing the Notch intracellular domain (NICD). NICD translocates to the nucleus, associates with the DNA-binding protein RBPJ, and recruits coactivators to drive transcription of downstream targets such as HES1, HEY1, HEY2, and MYC. This signaling cascade is subject to regulation by upstream factors TP53, NF-??B, and TGF-??, and it intersects with pathways controlling epithelial-mesenchymal transition, angiogenesis, and cellular differentiation. Consequently, JAG2 serves as a pivotal upstream regulator of Notch-dependent gene expression.
In esophageal squamous cell carcinoma, Notch pathway activity exerts pleiotropic effects that can promote or suppress tumor progression depending on cellular context. JAG2-mediated activation may enhance proliferation, stemness, or, alternatively, drive differentiation. The JAG2 Knockout TE1 Polyclonal Cells enable precise dissection of these roles, facilitating assays that measure changes in proliferation, wound healing, and gene expression. Moreover, this model allows investigation of cross-regulatory interactions with NF-??B and TGF-?? pathways, which are frequently dysregulated in esophageal cancers.
Typical research applications encompass Notch signaling studies, cancer biology, drug target validation, and developmental biology. Compatible assays include Western blotting and RT-qPCR for confirming JAG2 disruption and quantifying target gene expression; Notch reporter and flow cytometry assays for pathway activity; co-immunoprecipitation for protein interactions; and functional assays like cell proliferation and wound healing. For technical inquiries or ordering information, please contact Ascent Research.
